Manuscripts and Publications

Filters: Author is Kapogiannis, Bill G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, D Harris R et al..  2018.  Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.. Clin Infect Dis. 66(2):220-228.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
T
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
S
Agwu AL, Bethel J, Hightow-Weidman LB, Sleasman JW, Wilson CM, Rudy B, Kapogiannis BG.  2012.  Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.. AIDS Patient Care STDS. 26(4):193-6.
Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB.  2012.  Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
R
M Fernández I, Harper GW, Hightow-Weidman LB, Kapogiannis BG, Mayer KH, Parsons JT, Rotheram-Borus MJane, Seña AC, Sullivan PS.  2021.  Research Priorities to End the Adolescent HIV Epidemic in the United States: Viewpoint.. JMIR Res Protoc. 10(1):e22279.
Neilan AM, DeMonte JB, Foote JHA, Karalius B, Patel K, Kapogiannis BG, Rudy BJ, Huszti H, M Fernández I, Hudgens MG et al..  2022.  Rates of Sexually Transmitted Infection Diagnoses Among US Youth With Perinatally and Nonperinatally Acquired HIV.. Sex Transm Dis. 49(3):223-230.
Cunningham CK, Rudy BJ, Xu J, Bethel J, Kapogiannis BG, Ahmad S, Wilson CM, Flynn PM.  2010.  Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States.. Pediatr Infect Dis J. 29(6):530-4.
P
M Fernández I, Huszti HC, Wilson PA, Kahana S, Nichols S, Gonin R, Xu J, Kapogiannis BG.  2015.  Profiles of Risk Among HIV-Infected Youth in Clinic Settings.. AIDS Behav. 19(5):918-30.
Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N et al..  2006.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.
Kapogiannis BG, Leister E, Siberry GK, Van Dyke RB, Rudy B, Flynn P, Williams PL.  2016.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.. AIDS. 30(6):889-98.
Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.  2012.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
O
Mulligan K, D Harris R, Monte D, Stoszek S, Emmanuel P, Hardin DS, Kapogiannis BG, Worrell C, Meyer WA, Sleasman J et al..  2010.  Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.. Clin Infect Dis. 50(1):106-14.
N
Nichols SL, Bethel J, Garvie PA, Patton DE, Thornton S, Kapogiannis BG, Ren W, Major-Wilson H, Puga A, Woods SP.  2013.  Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus.. J Adolesc Health. 53(6):763-71.
M
Knopf AS, Gilbert ALewis, Zimet GD, Kapogiannis BG, Hosek SG, J Fortenberry D, Ott MA.  2017.  Moral conflict and competing duties in the initiation of a biomedical HIV prevention trial with minor adolescents.. AJOB Empir Bioeth. 8(3):145-152.
Knopf AS, Ott MA, Liu N, Kapogiannis BG, Zimet GD, J Fortenberry D, Hosek SG.  2017.  Minors' and Young Adults' Experiences of the Research Consent Process in a Phase II Safety Study of Pre-exposure Prophylaxis for HIV.. J Adolesc Health. 61(6):747-754.
L
Mulligan K, D Harris R, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, Monte D, Sleasman J, Wilson CM, Aldrovandi GM.  2012.  Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.. Clin Infect Dis. 55(3):461-8.
I
Lee S, Kapogiannis BG, Allison S.  2019.  Improving the Youth HIV Prevention and Care Continuums: The Adolescent Medicine Trials Network for HIV/AIDS Interventions.. JMIR Res Protoc. 8(3):e12050.
J Fortenberry D, Koenig LJ, Kapogiannis BG, Jeffries CL, Ellen JM, Wilson CM.  2017.  Implementation of an Integrated Approach to the National HIV/AIDS Strategy for Improving Human Immunodeficiency Virus Care for Youths.. JAMA Pediatr. 171(7):687-693.
Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, Bethel J, Luzuriaga K.  2010.  Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination.. Vaccine. 28(21):3672-8.
Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.  2013.  Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.. Clin Infect Dis. 57(5):735-44.
Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G et al..  2015.  Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.. J Acquir Immune Defic Syndr. 69(1):52-60.
H
Lally MA, van den Berg JJ, Westfall AO, Rudy BJ, Hosek SG, J Fortenberry D, Monte D, Tanney MR, McFarland EJ, Xu J et al..  2018.  HIV Continuum of Care for Youth in the United States.. J Acquir Immune Defic Syndr. 77(1):110-117.
Kapogiannis BG, Koenig LJ, Xu J, Mayer KH, Loeb J, Greenberg L, Monte D, Banks-Shields M, J Fortenberry D.  2020.  The HIV Continuum of Care for Adolescents and Young Adults Attending 13 Urban US HIV Care Centers of the NICHD-ATN-CDC-HRSA SMILE Collaborative.. J Acquir Immune Defic Syndr. 84(1):92-100.
E
Rubinstein ML, D Harris R, Rudy BJ, Kapogiannis BG, Aldrovandi GM, Mulligan K.  2014.  Exploration of the Effect of Tobacco Smoking on Metabolic Measures in Young People Living with HIV.. AIDS Res Treat. 2014:740545.
Ellen JM, Greenberg L, Willard N, Korelitz J, Kapogiannis BG, Monte D, Boyer CB, Harper GW, Henry-Reid LM, Friedman LB et al..  2015.  Evaluation of the effect of human immunodeficiency virus-related structural interventions: the connect to protect project.. JAMA Pediatr. 169(3):256-63.
Miller RLin, Boyer CB, Chiaramonte D, Lindeman P, Chutuape K, Cooper-Walker B, Kapogiannis BG, Wilson CM, J Fortenberry D.  2017.  Evaluating Testing Strategies for Identifying Youths With HIV Infection and Linking Youths to Biomedical and Other Prevention Services.. JAMA Pediatr. 171(6):532-537.
D
Whiteley LB, Brown LK, Swenson R, Kapogiannis BG, Harper GW.  2014.  Disparities in mental health care among HIV-infected youth.. J Int Assoc Provid AIDS Care. 13(1):29-34.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N et al..  2017.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
C
Lee S, Kapogiannis BG, Flynn PM, Rudy BJ, Bethel J, Ahmad S, Tucker D, Abdalian SEllen, Hoffman D, Wilson CM et al..  2013.  Comprehension of a simplified assent form in a vaccine trial for adolescents.. J Med Ethics. 39(6):410-2.
Boyer CB, Robles-Schrader GM, Li SX, Miller RL, Korelitz J, Price GN, Torres CMRivera, Chutuape KS, Stines SJ, Straub DM et al..  2014.  A comparison of network-based strategies for screening at-risk Hispanic/Latino adolescents and young adults for undiagnosed asymptomatic HIV infection.. J Adolesc Health. 55(6):765-73.
Li Y, Ni R, Song W, Shao W, Shrestha S, Ahmad S, Cunningham CK, Flynn PM, Kapogiannis BG, Wilson CM et al..  2009.  Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth.. Hum Genet. 126(5):685-96.
Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG et al..  2020.  Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
B
Kahn JA, Xu J, Kapogiannis BG, Sleasman JW.  2017.  Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.. J Acquir Immune Defic Syndr. 75(2):241-245.
Kahn JA, Rudy BJ, Xu J, Secord EA, Kapogiannis BG, Thornton S, Gillison ML.  2015.  Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth.. Sex Transm Dis. 42(5):246-52.
Butame SA, De Leon JM, Lee S-J, Naar S, Genn L, Dark T, Kapogiannis BG.  2021.  Barriers and Facilitators to the Collection and Aggregation of Electronic Health Record HIV Data: An Analysis of Study Recruitment Venues Within the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN).. Eval Health Prof. 44(2):168-176.
A
Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2013.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 57(11):5619-28.
Boyer CB, Hightow-Weidman L, Bethel J, Li SX, Henry-Reid L, Futterman D, Maturo D, Straub DM, Howell K, Reid S et al..  2013.  An assessment of the feasibility and acceptability of a friendship-based social network recruitment strategy to screen at-risk African American and Hispanic/Latina young women for HIV infection.. JAMA Pediatr. 167(3):289-96.
Syed SS, Balluz RS, Kabagambe EK, Meyer WA, Lukas S, Wilson CM, Kapogiannis BG, Nachman SA, Sleasman JW.  2013.  Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.. AIDS Res Hum Retroviruses. 29(3):493-500.
Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, E Patton D, Ren W, Thornton SE, Major-Wilson HO, Puga AM et al..  2016.  Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.. J Neurovirol. 22(2):218-30.
Gilbert ALewis, Knopf AS, J Fortenberry D, Hosek SG, Kapogiannis BG, Zimet GD.  2015.  Adolescent Self-Consent for Biomedical Human Immunodeficiency Virus Prevention Research.. J Adolesc Health. 57(1):113-9.